Dynamics and Compositional Profiles of Human Milk Oligosaccharides in Mothers with Gestational Diabetes Mellitus Across Lactation

Why It Matters

Reduced and altered HMO profiles in GDM mothers could compromise infant gut microbiome development and immune protection, highlighting a need for targeted nutritional strategies. The findings inform clinicians, lactation consultants, and infant‑formula developers about metabolic impacts on breast‑milk quality.

Key Takeaways

• GDM mothers' total HMO levels lower across all lactation stages
• Seven specific HMOs, including 2'-FL, linked to gestational diabetes
• HMOs decline sharply after colostrum, especially at 1‑month
• DSLNT and LacNAC drop faster in GDM mothers at 8‑14 days
• Temporal HMO patterns may affect infant gut microbiome development

Pulse Analysis

Human milk oligosaccharides are the third most abundant solid component in breast milk and serve as prebiotics, anti‑adhesive agents, and immune modulators for newborns. As gestational diabetes mellitus affects up to 10% of pregnancies worldwide, understanding how maternal metabolic disturbances reshape milk composition is critical for pediatric health. Recent advances in ultra‑performance liquid chromatography–tandem mass spectrometry have enabled precise quantification of dozens of HMOs, allowing researchers to map subtle biochemical shifts that were previously invisible.

The Danyang City study revealed that mothers with GDM consistently produced lower total HMO concentrations from colostrum through three months postpartum. Seven individual sugars—most notably 2'-fucosyllactose, lacto‑N‑difucohexaose I, and 3'-sialyl‑N‑acetyl‑lactosamine—showed statistically significant reductions after adjusting for maternal age, BMI, gestational age and glucose levels. Moreover, the temporal trajectory of HMOs differed: while most sugars declined after the first week, DSLNT and N‑acetyl‑lactosamine fell markedly faster in the GDM group during the second‑week window, suggesting an interaction between early lactation dynamics and diabetic physiology.

These biochemical insights have practical implications. Lower HMO availability may alter the infant’s gut microbiota, potentially increasing susceptibility to infections or metabolic programming issues later in life. For formula manufacturers, the data underscore the value of supplementing specific HMOs—especially fucosylated and sialylated variants—to mimic the protective profile of healthy breast milk. Clinicians may also consider monitoring infant growth and gut health more closely when mothers have GDM, and future research should explore whether dietary or pharmacologic interventions during pregnancy can normalize HMO secretion. The study adds a crucial piece to the puzzle of how maternal health translates into neonatal nutrition.